The benign prostatic hyperplasia treatment market is projected to reach USD 14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. The growth of this market is driven by the increasing prevalence of benign prostatic hyperplasia, the rising preference for minimally invasive surgeries, increasing obesity rate, and investments, funds, and grants for research in the field of BPH treatment.
Browse 130 market data Tables and 40 Figures spread through 158 Pages and in-depth TOC on "Benign Prostatic Hyperplasia Treatment Market"
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198000374
North America commanded the largest share of the benign prostatic hyperplasia treatment market in 2021.
On the basis of region, the benign prostatic hyperplasia treatment market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2019, North America commanded the largest share of the benign prostatic hyperplasia treatment market. The large share of this market segment can be attributed to the rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market.
The major players operating in this market are Boston Scientific Corporation (US), Coloplast Group (Denmark), Teleflex Incorporated (US), Olympus Corporation (Japan), GlaxoSmithKline PLC (UK), Eli Lilly (US), Pfizer, Inc. (US), Abbott (US), Asahi Kasei Corporation (Japan), Merck & Co., Inc. (US), Astellas Pharma Inc. (Japan), Allergan plc (Ireland), Alembic (India), IPG Photonics Corporation (US), Richard Wolf GmbH (Germany), Unilab, Inc. (Philippines), Pharex Health Corporation (Philippines), Biolitec AG (Austria), Urologix, LLC (US), Advin Health Care (India), Medifocus, Inc. (Canada), Asclepion Laser Technologies GmbH (Germany), Pnn Medical A/S (Denmark), Surgical Lasers Inc. (Canada). Quanta Systems (Italy), Allium Ltd. (Israel), Lumenis Ltd. (Israel), KARL STORZ SE & Co. KG (Germany), and SRS Medical (US).
For more details: https://www.marketsandmarkets.com/Market-Reports/benign-prostatic-hyperplasia-treatment-market-198000374.html
OPPORTUNITY: Promising Product Pipeline
The BPH treatment market offers considerable growth opportunities to manufacturers of generics. The patents of most medications for BPH treatment such as Avodart, Cialis, and Jalyn have expired, which has paved the way for generics. Besides, demand has also risen for more effective treatment options, resulting in a strong pipeline of products in the BPH market.
Benign Prostatic Hyperplasia Treatment
US EVERY YEAR FOR THEIR
HOME ❯ TOP MARKET REPORTS ❯ BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET
Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha
Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors
(Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA],
End User (Hospitals) - Global Forecast to 2026
[158 Pages Report] The benign prostatic hyperplasia treatment market is projected to reach USD
14.1 billion by 2026 from USD 10.8 billion in 2021, at a CAGR of 5.3% from 2021 to 2026. The
presence of a large geriatric and target patient population and the improving healthcare
infrastructure in several APAC countries are expected to offer growth opportunities in the market
during the forecast period.
To know about the assumptions considered for the study, Request for Free Sample Report
Covid -19 Impact On The Benign Prostatic Hyperplasia Treatment Market
The market for BPH treatment is anticipated to be considerably affected due to the outbreak of
COVID-19. Since hospitals would face a huge demand for resources to fight against a possible
increase of COVID-19 cases, elective surgeries of benign pathology had been recommended to be
delayed until the strain on the hospital system from COVID-19 decreases. Owing to this, surgical
procedures such as TURP, HoLEP, ThuLEP, and PVP had been postponed.
According to a recent study, nearly 2.5 million urological benign surgeries were estimated to be
canceled during the peak of disruption by COVID-19. However, the number of alternative surgical
procedures has increased. For instance, laser treatment can be adopted by additional surgery
centers and other outpatient facilities not focused on COVID-19 patients.
DRIVER:Increasing prevalence of benign prostatic hyperplasia
BPH refers to the nonmalignant growth of prostate tissue and is a frequent cause of low